Kyverna Therapeutics, Inc. (KYTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Kyverna Therapeutics, Inc. (KYTX) closed at USD 5.97 on 2026-10-15, a change of -16.7 % over the past year, with a market capitalization of USD 350.65M.

Kyverna Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Kyverna Therapeutics, Inc. key figures

Previous close

USD 5.97 (2026-10-15)

1-year change

-16.7 %

Market cap

USD 350.65M

Enterprise value

USD 184.22M

P/E ratio (trailing)

-1.94

P/E ratio (forward)

-1.79

EPS (trailing)

-2.93

EPS (forward)

-3.17

PEG ratio

n/a

Price to book

2.11

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.19

Employees

149

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Kyverna Therapeutics, Inc. and compare it with other stocks.